CD23 Antibody

Immunohistochemistry (FFPE): 1-2ug/ml for 30 min at RT

Optimal dilution of the CD23 antibody should be determined by the researcher.
1. The prediluted format is supplied in a dropper bottle and is optimized for use in IHC. After epitope retrieval step (if required), drip mAb solution onto the tissue section and incubate at RT for 30 min.

The protein recognized by this MAb is identified as human leukocyte differentiation antigen CD23 (FCE2). It is a type II integral membrane glycoprotein that is expressed on mature B cells, monocytes, eosinophils, platelets and dendritic cells. CD23 is a low affinity IgE receptor that mediates IgE-dependent cytotoxicity and phagocytosis by macrophages and eosinophils. CD23 associates as an oligomer where cooperative binding of at least two lectin domains is required for high affinity IgE binding to CD23. It may play a role in antigen presentation by B cells by interacting with CD40. CD23 has been shown to be associated with the Fyn tyrosine kinase. The truncated molecule can be secreted, then function as a potent mitogenic growth factor. CD23 is expressed on a subpopulation of peripheral blood cells, B-lymphocytes and on EBV transformed B lymphoblastoid cell lines. CD23 is also detected in neoplastic cells from cases of B cell chronic lymphocytic leukemia and some cases on centroblastic/centrocytic lymphoma.

Purified

0.2 mg/ml in 1X PBS with 0.1 mg/ml BSA (US sourced) and 0.05% sodium azide

A recombinant human FCER2/CD23 protein fragment within amino acids 48-321 was used as the immunogen for the CD23 antibody.

This CD23 antibody is available for research use only.

Cell surface, cytoplasmic

Yes

Protein G affinity chromatography

Human

P06734